GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
RSS SUMMARY · AGGREGATED FROM CNBC
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
US
SpaceX IPO explained: The price is set, but retail allocation still up in the air
CNBC·1h ago·3 min read
Business
As LIV Golf faces a Saudi funding cliff, CEO says to take PIF ‘at their word’
CNBC·1h ago·3 min read
US
Jeffrey Epstein’s former assistant Lesley Groff interviewed by House panel
CNBC·2h ago·3 min read
US
House Republicans push $70 billion immigration funding package toward passage
CNBC·1h ago·3 min read
Related
On this beat
Health
Health Care Roundup: Market Talk
TWSJ·2h ago·3 min read
Health
Our writer was the first paying customer at Faena New York’s sprawling Tierra Santa wellness space. She tried every pool.
TWSJ·2h ago·3 min read
Health
Homemade Fudgesicles Recipe (Clean Ingredients)
WELNESS MAMA·7h ago·3 min read
Health
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
CNBC·11h ago·3 min read